{"name":"Allysta Pharmaceutical","slug":"allysta-pharmaceutical","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNNm9XbzF5bVktelpDeFdtNWdRUnlpWmFOTjJ2NnphaDBZUlNMUGIxUERUcWxUMUlraGxGZ3lCbTdoR1BqTXNCS29Db3BPUXlIaGJHLXlwSzFSeWxCMGl5WG1kOWpfREVuZ3gzaWhEQ3ZOd3FEaExQOUMycGtvMm13Wm5TakVGbkNVRjNnZnpLWTlmQlNsRkttajFxMTlGM3JwVlZlcnJmRGZrRUMtZklXbktQUThMbkFXMmdhVGJGRHBUNTJDUHYwN3BuVU1JcHc1cXVLMVpTbDNlR3JqdGkwTUtDdkFHWXJGS3c?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart","summary":"Ocular Hypertension Pipeline Demonstrates Strong Momentum with 50+ Companies Advancing 75+ Therapies | DelveInsight - Barchart","headline":"Ocular Hypertension Pipeline Demonstrates Strong Momentum with 50+ Companies Advancing 75+ Therapies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-12","type":"pipeline","source":"globenewswire.com","summary":"Peptide Therapeutics Market Trends and Global Forecasts to - globenewswire.com","headline":"Peptide Therapeutics Market Trends and Global Forecasts to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOTlQzRkpQQlZDZXVlTFU3RzJWVV9HN3RhdWxyQ1gxdGJDaHFvZWpFQy1tOWRDbXhESDk2RkVWajdQZ2NhSTFncGlxTF9WTEVXMTdYZlhWdmd6NVI3b1FTbGdCZjNGTXBrVWp3S19GUF9DZlh0OFF3RXI0cU1XMFZhVXFzZjJZVkNpUU95bm9Jc0Y3Sm9yMkFoQ1dTTzNPb29PY0MwZ2VWaXJNR3d0WHgtY1BXV0FFWlMzZFRwdGl6VmR5U2xGMUNSLTRLdm9UQ2p6dVlvYU1BemYySTVLTE5va3ZFdmxvb0thRXNUNzlCVWJld0VuUDZn?oc=5","date":"2025-09-09","type":"pipeline","source":"PR Newswire","summary":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight - PR Newswire","headline":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPVlpNZmlUVkVjeXZPRlkwRy1Vd29rNUU1dmxFT25taERrbkRoeWxBQWp1N3RwVHNRYXhIcTJCQnNDZE9mejlTYS1lQmxnWUxib0lfNHkzdHdIR0c4bG83ejNMSDUzM0MyNThFVXVxZzhwNWhHVkVDcVJfTFZnci1HSU5NSW5IT0pZYUtXcDduMFVPTl9BSUE?oc=5","date":"2024-09-30","type":"pipeline","source":"Frontiers","summary":"Dissecting the importance and origin of circulating myokines in gastric cancer cachexia - Frontiers","headline":"Dissecting the importance and origin of circulating myokines in gastric cancer cachexia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE50QWFYcDdzclJZcnQwNnlyNy1rbXdpdzlYOHdOMFlIN0NHYTNXNGRjZnh4LTF6d1AwVDBmb3FyOVczZ0taVmk5dFYxV2hjLU1rODNZTjZQQkVhZEh4S3hFbjJ6WFU0T0NHa21ndlFSRk84Zw?oc=5","date":"2024-06-07","type":"pipeline","source":"Wiley","summary":"The adiponectin-derived peptide ALY688 protects against the development of metabolic dysfunction-associated steatohepatitis - Wiley","headline":"The adiponectin-derived peptide ALY688 protects against the development of metabolic dysfunction-associated steatohepati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPOHJTdW1mV3E1MHlfN1VJWkRUeHpGUEVmTmtiaXNvSVZQUHhVOExIT01CN1J5VHEzUUNfNXlqa2JneDVqaHlBTC02N0otbFgzWVoydXJPLWV5TmFCYV9VdnBlWDE1SXNnSXBPbTlfcHNTR1FmYUQtbElKWDE1SGRNamhob2JINXF1U2ZUZk92cjdSN09vZl9QUUF6SzFMMW5kb0JYUkFjcUxpd2pnOHdWZ01MOVJKdkQxTUlKSUtIRmtHUnRJZjVmWWlZNENRblZ5bUMtajZZYXl3Z21xanc?oc=5","date":"2022-11-11","type":"trial","source":"Ophthalmology Times","summary":"Allysta Pharmaceuticals announces completion of enrollment in OASIS-1 phase 2b/3 clinical trial of ALY688 - Ophthalmology Times","headline":"Allysta Pharmaceuticals announces completion of enrollment in OASIS-1 phase 2b/3 clinical trial of ALY688","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOUFNtQko1MXh5UVRUTXNFSzBzX3FubnJ2X0tUcXVpUGxfcVJ5bWNia3V1QmxRcThVb0NaNjg3NWFwS29rclVrUkNWbW13SUxGRnM1d3BBTjFhbzJ0LURQR2MwdUx0WG1pNDliQmhpV3BVTldEa2Q1dXJGNXZFemZjRjlJMmhuc3UxXzJPVWlUdlJOekRXNkVvX3Rn?oc=5","date":"2022-11-08","type":"trial","source":"Yahoo Finance","summary":"Allysta Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2b/3 Clinical Trial (OASIS-1) Evaluating the Efficacy and Safety of ALY688 Ophthalmic Solution in Dry Eye Disease - Yahoo Fina","headline":"Allysta Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2b/3 Clinical Trial (OASIS-1) Evaluating the E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxQYzFiVTIzMVluckFYZDUybkpoM1lseGdTdUFNdFBJY21ZM3lvbHZTbDk5WWJXSWZTNzZ3WHdHaUhaejZwYTZDdGxncGg2NVVwRlNrQUdBYjdsTTdkRGN1bXZIZ2tKNXQtanN1VmNtS1AyNmJvWDhBUFpFRHdiRVVmTXl4REFiOEowLWNYSWpPdE5LeVhHT3FqMEJUMVNoUkRGeXdCeWkyeWdlR1djN2hSaUJ6eUxTMFNyTlVRbW9ka2hneGZsVExrcE1WVjEzYXk4MTgwRkctWGtzMUZWdkdoUk9rWEZiOXFPVVZvX1hNWTFUVG9aMEZzcHJSNjFrcWxoc05VeXpHNVBqTkl3X3ZzZGxrdlhrUTFlRWxBU3NkdXktSUJDaHRVajc4ZzBRUndyRFQ0Yy1mRG1QX1RfTVNzYkQ1dU02TTM3aG9CN3NDN3FOYVpGWnc?oc=5","date":"2022-03-24","type":"pipeline","source":"globenewswire.com","summary":"Peptide Therapeutics: Contract API Manufacturing Market - globenewswire.com","headline":"Peptide Therapeutics: Contract API Manufacturing Market","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}